Biography

Andrew Osnowski brought a decade of experience in the chemical optimisation of new drug candidates to the group. Prior to joining the group he was Medicinal Chemistry Team Leader at Scottish Biomedical, where he was responsible for the management of research teams engaged in the contracted development of new pharmaceutical agents for an international roster of commercial clients. During this time, teams under his management successful advanced a number of client projects from hit compounds through to optimised “drug-like“ products. Prior to his four years with Scottish Biomedical, Mr Osnowski held a series of research chemist positions in biotechnology and pharmaceutical companies, including two years in the medicinal chemistry team at Cyclacel Pharmaceuticals, a developer of kinase inhibitor drugs for the treatment of cancer. He holds a first-class honours degree in Chemistry from the University of Strathclyde.

Andrew worked in the group from July 2008 to June 2009, after which he left to start an organic chemistry PhD in Scotland.